IPM001 / Immupeutics Medicine - LARVOL DELTA

Phase I study of IPM001 injection in advanced hepatocellular carcinoma: Safety, tolerability, and preliminary efficacy (ESMO 2025) - P1 | "Pharmacodynamic findings confirm in vivo CTL expansion and antigen-specific responses. These datasupportfurther evaluation of IPM001 in larger, controlled trials."

Clinical • Metastases • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • IFNG

The IND of IPM001 injection was implicitly approved by the NMPA [Google translation] (vbdata.cn) - "Zhenzhi Medical's IPM001 injection has been implicitly approved by the NMPA for the treatment of advanced liver cancer..."

New trial • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor

Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Peking Union Medical College Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital

New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor